Scynexis Inc (SCYX)

概要ニュース株価時系列オプションチェーン Financials なぜSCYXが下落しているのか？ディスカッション予測株式分割

Relative Volume:

ネットキャッシュフロー:

Scynexis Inc Stock (SCYX) Company Profile

Scynexis Inc

Healthcare (1166)

201-884-5485

1 EVERTRUST PLAZA, JERSEY CITY, NJ

SCYX's Discussions on Twitter

SCYX を他の銘柄と比較する

株式	価格	時価総額	収益	当期純利益	現金流量	EPS
SCYX Scynexis Inc	1.00	40.54M	135.87M	72.20M	45.09M	1.42
ZTS Zoetis Inc	163.11	73.07B	9.26B	2.49B	2.30B	5.47
TAK Takeda Pharmaceutical Co Adr	15.05	47.43B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.24	45.72B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	15.08	17.28B	16.54B	-1.64B	749.00M	-1.45
ITCI Intra Cellular Therapies Inc	131.81	14.03B	612.78M	-86.37M	-62.91M	-0.87

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

日付	アクション	アナリスト	評価の変更
2021-01-22	開始されました	Guggenheim	Buy
2021-01-06	開始されました	Cantor Fitzgerald	Overweight
2018-07-11	アップグレード	Needham	Hold → Buy
2018-06-27	開始されました	Maxim Group	Buy
2017-10-24	開始されました	Guggenheim	Buy
2017-07-10	開始されました	ROTH Capital	Buy
2017-05-09	ダウングレード	Needham	Buy → Hold
2017-03-03	繰り返されました	RBC Capital Mkts	Outperform
2016-10-20	開始されました	H.C. Wainwright	Buy
2016-10-07	アップグレード	WBB Securities	Buy → Strong Buy
2016-10-03	再開されました	Brean Capital	Buy
2016-08-17	開始されました	Guggenheim	Buy
2016-08-09	繰り返されました	Needham	Buy
2016-08-09	アップグレード	WBB Securities	Speculative Buy → Buy
2016-03-28	開始されました	Brean Capital	Buy
2015-12-29	開始されました	WBB Securities	Speculative Buy
2015-11-16	繰り返されました	RBC Capital Mkts	Outperform
2015-06-10	開始されました	Needham	Buy
2014-05-29	開始されました	Canaccord Genuity	Buy
2014-05-29	開始されました	RBC Capital Mkts	Outperform

Scynexis Inc (SCYX) 最新ニュース

Scynexis Inc (SCYX) 財務データ

Scynexis Inc (SCYX)

Scynexis Inc Stock (SCYX) Company Profile

SCYX を他の銘柄と比較する

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

Scynexis Inc (SCYX) 最新ニュース

SCYNEXIS (NASDAQ:SCYX) Lowered to Sell Rating by StockNews.com - Defense World

SCYNEXIS (SCYX) to Release Earnings on Thursday - Defense World

Research Analysts Issue Forecasts for SCYNEXIS FY2029 Earnings - Defense World

StockNews.com Downgrades SCYNEXIS (NASDAQ:SCYX) to Sell - Defense World

SCYNEXIS Full Year 2024 Earnings: Misses Expectations - Yahoo Finance

SCYNEXIS Reports 2024 Financial Results and Updates - TipRanks

Scynexis Inc earnings beat by $0.06, revenue fell short of estimates - Investing.com Australia

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times

SCYNEXIS, Inc. Advances Phase 1 Trial of SCY-247 Antifungal and Prepares for Phase 3 MARIO Study Restart - Nasdaq

SCYX stock touches 52-week low at $0.89 amid market challenges - Investing.com Australia

NanoNewron Appoints Industry Veteran Marco Taglietti, M.D., as Chief Executive Officer to Lead the Company and the Development of Their Promising Alzheimer’s Compound - Yahoo Finance

EQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of SCYNEXIS, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 8, 2017SCYX - ACCESS Newswire

SCYNEXIS (NASDAQ:SCYX) Stock Crosses Below 200-Day Moving Average – Time to Sell? - Defense World

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of SCYNEXIS, Inc. (SCYX) Investigation - ACCESS Newswire

SCYNEXIS (NASDAQ:SCYX) Share Price Passes Below 200-Day Moving Average – Should You Sell? - Defense World

Geode Capital Management LLC Acquires 36,405 Shares of SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

FEDERATED HERMES, INC. Reduces Stake in SCYNEXIS Inc: A Detailed Analysis - GuruFocus.com

Aspergillosis Market Expected to rise, 2034 | Regeneron, Pulmocide, Astellas Pharma, Cipla, Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, I - The Globe and Mail

SCYNEXIS, Inc. (NASDAQ:SCYX) Short Interest Update - Defense World

Stay Ahead in Ophthalmology: Strategic Market Insights for Myopia Assessment & Forecasting | DelveInsight - GlobeNewswire Inc.

SCYX stock touches 52-week low at $0.97 amid market challenges - Investing.com

SCYNEXIS, Inc. Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections - Marketscreener.com

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections - The Manila Times

SCYNEXIS Launches Pivotal Phase 1 Trial for Novel Antifungal Drug Against Deadly Infections - StockTitan

SCYX stock touches 52-week low at $1.15 amid market challenges - Investing.com Canada

Comparing Madrigal Pharmaceuticals (NASDAQ:MDGL) & SCYNEXIS (NASDAQ:SCYX) - Defense World

SCYNEXIS (NASDAQ:SCYX) adds US$6.5m to market cap in the past 7 days, though investors from five years ago are still down 86% - Simply Wall St

Avidity Partners Management LP's Strategic Acquisition in SCYNEX - GuruFocus.com

Federated Hermes, Inc. Increases Stake in SCYNEXIS Inc - GuruFocus.com

SCYX stock touches 52-week low at $1.25 amid market challenges By Investing.com - Investing.com South Africa

SCYX stock touches 52-week low at $1.25 amid market challenges - Investing.com

SCYNEXIS announces new $50 million equity sales agreement By Investing.com - Investing.com Australia

SCYNEXIS Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times

Scynexis Inc earnings beat by $0.08, revenue fell short of estimates - Investing.com Canada

Scynexis: Q3 Earnings Snapshot - San Francisco Chronicle

SCYNEXIS announces new $50 million equity sales agreement - Investing.com India

SCYNEXIS Secures $10M GSK Milestone, Advances Antifungal Pipeline Despite Q3 Revenue Dip | SCYX Stock News - StockTitan

SCYNEXIS, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Scynexis Inc (SCYX) 財務データ

収益

当期純利益

現金流量

EPS

SCYXに似た銘柄